ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
120.269,31
-0,67%
S&P 500
5.970,84
-1,11%
US Dollar vs BRL
6,19575
0,00%
Bitcoin
95.104,82
1,00%
Brent Oil
73,44
0,00%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Soligenix Inc (SNGX)

  7. Soligenix Inc (SNGX) Notícias

SNGX

Soligenix (SNGX)

Soligenix Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SNGX
DataHoraFonteTítuloCódigoCompanhia
16/12/202409:30PR Newswire (US)Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell LymphomaNASDAQ:SNGXSoligenix Inc
13/12/202419:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
02/12/202409:30PR Newswire (US)HyBryte™ Clinical Results Demonstrate Continued Improvement Post-TreatmentNASDAQ:SNGXSoligenix Inc
19/11/202409:30PR Newswire (US)Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell LymphomaNASDAQ:SNGXSoligenix Inc
14/11/202409:15PR Newswire (US)Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's DiseaseNASDAQ:SNGXSoligenix Inc
08/11/202418:14Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SNGXSoligenix Inc
08/11/202418:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNGXSoligenix Inc
08/11/202409:30PR Newswire (US)Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial ResultsNASDAQ:SNGXSoligenix Inc
24/10/202408:30GlobeNewswire Inc.Soligenix, Inc. to Present at the 2024 ThinkEquity ConferenceNASDAQ:SNGXSoligenix Inc
22/10/202408:30PR Newswire (US)Soligenix Receives Hong Kong Patent for Improved Production of Synthetic HypericinNASDAQ:SNGXSoligenix Inc
16/10/202408:30PR Newswire (US)Soligenix Invited to Present at Upcoming Investor ConferencesNASDAQ:SNGXSoligenix Inc
11/10/202417:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNGXSoligenix Inc
07/10/202408:30PR Newswire (US)HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer ConferenceNASDAQ:SNGXSoligenix Inc
03/10/202408:30PR Newswire (US)Soligenix Announces Partnership with Sterling Pharma SolutionsNASDAQ:SNGXSoligenix Inc
16/09/202408:30PR Newswire (US)Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024NASDAQ:SNGXSoligenix Inc
03/09/202408:30PR Newswire (US)Soligenix Receives European Patent for Improved Production of Synthetic HypericinNASDAQ:SNGXSoligenix Inc
16/08/202417:19Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SNGXSoligenix Inc
09/08/202408:30PR Newswire (US)Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial ResultsNASDAQ:SNGXSoligenix Inc
05/08/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SNGXSoligenix Inc
01/08/202410:00GlobeNewswire Inc.Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian PoligoneNASDAQ:SNGXSoligenix Inc
15/07/202411:16GlobeNewswire Inc.PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study ResultsNASDAQ:SNGXSoligenix Inc
09/07/202408:30PR Newswire (US)Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell LymphomaNASDAQ:SNGXSoligenix Inc
25/06/202408:30PR Newswire (US)Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell LymphomaNASDAQ:SNGXSoligenix Inc
14/06/202408:30PR Newswire (US)A Comparison of Vaccine Technologies to be Presented at the ASM Microbe ConferenceNASDAQ:SNGXSoligenix Inc
05/06/202409:00GlobeNewswire Inc.Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication TrialNASDAQ:SNGXSoligenix Inc
31/05/202408:30PR Newswire (US)Soligenix Announces Reverse Stock SplitNASDAQ:SNGXSoligenix Inc
29/05/202417:05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SNGXSoligenix Inc
29/05/202408:30PR Newswire (US)Soligenix Encourages Stockholders to Vote their Shares at the Annual MeetingNASDAQ:SNGXSoligenix Inc
24/05/202408:30PR Newswire (US)Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual MeetingNASDAQ:SNGXSoligenix Inc
23/05/202408:30PR Newswire (US)Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock SplitNASDAQ:SNGXSoligenix Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:SNGX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
BRAV3
Brava Energia ON
BOV
RCSL4
RECRUSUL PN
BOV
FICT3
Fictor Alimentos ON
BOV
CVCB3
CVC BRASIL ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
AMER3
Americanas ON
BOV
IRBR3
IRB BRASIL ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados